In a report released today, Francois Brisebois from Oppenheimer maintained a Buy rating on Cybin (CYBN – Research Report), with a price target of $4.50. The company’s shares closed last Friday at $0.34.
According to TipRanks, Brisebois is an analyst with an average return of -6.9% and a 33.64% success rate. Brisebois covers the Healthcare sector, focusing on stocks such as Cybin, Avadel Pharmaceuticals, and Achieve Life Sciences.
Currently, the analyst consensus on Cybin is a Moderate Buy with an average price target of $4.75, representing a 1,308.66% upside. In a report released on February 15, H.C. Wainwright also reiterated a Buy rating on the stock with a $5.00 price target.
See the top stocks recommended by analysts >>
The company has a one-year high of $0.74 and a one-year low of $0.21. Currently, Cybin has an average volume of 3.56M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Cybin (CYBN) Company Description:
Using cutting-edge drug discovery platforms and drug delivery systems, Cybin develops psychedelic therapies to address the mental health crisis.
Read More on CYBN:
